Bayer HealthCare reports positive trial data for VEGF Trap-Eye

Bayer HealthCare has published positive new clinical trial data from two parallel phase III studies of VEGF Trap-Eye for age-related macular degeneration (wet AMD).

In association with partner Regeneron Pharmaceuticals, the company has published integrated analysis from the trials which showed sustained improvement in visual acuity among trial participants at 96 weeks compared to baseline.

Over the course of the first year of the View 1 and View 2 studies, three different dosing regimens were trialled in comparison to a leading alternative, with results also showing that VEGF Trap-Eye patients require fewer injections.

This data will help to support the companies' European and Japanese applications for regulatory approval of the drug for wet AMD patients, which were filed earlier this year.

Dr Kemal Malik, member of the Bayer HealthCare executive committee and chief medical officer, said: "Less frequent office visits, predictable every-other-month dosing in the first year and fewer injections in the second year may have the potential to significantly reduce the burden for patients."

It comes after the company commenced a new VEGF Trap-Eye phase III study for wet AMD patients in China last month.